Compounds > sb 203580
Page last updated: 2024-09-05

sb 203580 and Arthritis

sb 203580 has been researched along with Arthritis in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, JL; Badger, AM; Boehm, JC; Bradbeer, J; Breton, JJ; Chabot-Fletcher, MC; Gallagher, TF; Garigipati, RS; Griswold, DE; Hillegass, LM; Laydon, JT; Lee, JC; Sheldrake, PL; Smietana, JM; Sorenson, ME1
Bhargava, A; Bombara, M; Caringal, Y; Dally, R; Dumas, J; Gunn, D; Housley, TJ; Johnson, JS; Kingery-Wood, J; Lee, W; Osterhout, M; Paulsen, H; Ranges, GE; Redman, AM; Renick, J; Scott, WJ; Shrikhande, A; Smith, RA; Swartz, S; Wild, H; Wilhelm, SM; Young, D1
Bankston, D; Bhargava, A; Bortolon, E; Caringal, Y; Chau, T; Chien, DS; Cooley, J; Dumas, J; Gianpaolo Ostravage, C; Gunn, D; Hatoum-Mokdad, H; Housley, TJ; Khire, U; Lee, W; Muzsi, A; Osterhout, M; Paulsen, H; Pirro, J; Ranges, GE; Redman, AM; Romero, R; Schoenleber, R; Scott, WJ; Shrikhande, A; Sibley, RN; Smith, RA; Wakefield, J; Wilhelm, SM; Wolanin, D; Wood, J1
Ali, S; Amir, M; Somakala, K1
Adams, JL; Badger, AM; Bradbeer, JN; Griswold, DE; Lee, JC; Votta, B1

Other Studies

5 other study(ies) available for sb 203580 and Arthritis

ArticleYear
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
    Journal of medicinal chemistry, 1996, Sep-27, Volume: 39, Issue:20

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arthritis; Bone Density; Cyclooxygenase Inhibitors; Cytokines; Imidazoles; Lipoxygenase Inhibitors; Mice; Mice, Inbred BALB C; Molecular Structure; Morpholines; Prostaglandin-Endoperoxide Synthases; Protein Kinases; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha

1996
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
    Bioorganic & medicinal chemistry letters, 2001, Jan-08, Volume: 11, Issue:1

    Topics: Arthritis; Enzyme Inhibitors; Furans; Humans; Inhibitory Concentration 50; Interleukin-6; Mitogen-Activated Protein Kinases; Molecular Structure; Osteoporosis; p38 Mitogen-Activated Protein Kinases; Pyrroles; Thiophenes; Tumor Cells, Cultured; Urea

2001
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
    Bioorganic & medicinal chemistry letters, 2002, Jun-17, Volume: 12, Issue:12

    Topics: Administration, Oral; Animals; Arthritis; Cytokines; Enzyme Inhibitors; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Urea

2002
p38 MAP kinase inhibitors as anti inflammatory agents.
    Mini reviews in medicinal chemistry, 2013, Volume: 13, Issue:14

    Topics: Amides; Animals; Anti-Inflammatory Agents; Arthritis; Binding Sites; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Humans; Imidazoles; Indoles; Inflammation; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Structure-Activity Relationship; Urea

2013
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
    The Journal of pharmacology and experimental therapeutics, 1996, Volume: 279, Issue:3

    Topics: Animals; Arachidonic Acid; Arthritis; Bone Resorption; Calcium-Calmodulin-Dependent Protein Kinases; Collagen; Disease Models, Animal; Enzyme Inhibitors; Female; Imidazoles; Male; Mice; Mice, Inbred Strains; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Rats, Inbred Lew; Shock, Septic; Tumor Necrosis Factor-alpha

1996